Wolfgang Miesbach: Base Editing and the Future of Sickle Cell Disease Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Base editing. Gene editing 2.0?
At EHA 2026, Maria Morelló Miravet (Karolinska Institutet, Stockholm) showed how precise base editing of hematopoietic stem cells (HSCs) can move from concept to clinic in sickle cell disease (SCD):
Unlike classical CRISPR‑Cas9 nucleases that rely on double‑strand breaks and stochastic indels, base editors convert single nucleotides at predefined sites using deaminases fused to a Cas9 nickase.
This enables highly controlled editing of regulatory elements such as HBG promoters or BCL11A‑related loci, with the goal of re‑inducing fetal hemoglobin (HbF) while limiting chromosomal rearrangements and p53‑mediated stress responses.
This presentation is a powerful reminder that academia can drive first‑in‑class, highly sophisticated innovative programs, from basic biology and manufacturing to regulatory strategy and clinical implementation ”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian